Real-World Analysis of Exacerbations and Exacerbation-Related Costs Among Patients with Asthma Receiving Tezepelumab (CROSSROADS-5) (20240066)

Study identification

• EU PAS number:
  EUPAS1000000514
• Study ID:
  1000000514
• Official title and acronym:
  Real-World Analysis of Exacerbations and Exacerbation-Related Costs Among Patients with Asthma Receiving Tezepelumab (CROSSROADS-5) (20240066)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This non-interventional, retrospective database analysis will describe treatment outcomes including asthma exacerbations and healthcare resource utilization and costs among severe asthma patients initiating tezepelumab and segmented by payer channel (with a special emphasis on the Medicare FFS population) and by prior biologic experience. ; Secondary and exploratory analyses will include a description of patterns of tezepelumab utilization and OCS dosing.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned:21/03/2024

Actual:21/03/2024

Study start date

Planned:31/03/2025

Actual:31/03/2025

Data analysis start date

Planned:31/03/2025

Date of final study report

Planned:30/10/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen 100%

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

20240066